Eltrombopag in Pediatric Severe Aplastic Anemia: Favorable Outcomes
Blood Journals Portfolio shared a post on X:
”Eltrombopag’s pharmacokinetics profile was similar to that seen in patients with immune thrombocytopenia, with no unexpected safety signals.”
Read the full article here.
Title: Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial
Authors: Akiko Shimamura, Alexey Maschan, Carolyn Bennett, Sujith Samarasinghe, Jason E. Farrar, Chi-kong Li, Nongnuch Sirachainan, Bunchoo Pongtanakul, Patcharee Komvilaisak, Ludmila Zubarovskaya, Jennifer A. Rothman, Kelly Walkovich, Taizo A. Nakano, Alison A. Bertuch, Anabela Ferrao, Rukhmi Bhat, Rabi Hanna, Kathleen Overholt, Jessica Boklan, Tze Fang Wong, Qinxia Wang, Patrick Urban, Brigitte Strahm, Winfred Wang, Adrianna Vlachos, David A. Williams
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Mar 9, 2026, 13:55Marios Georgakis: GLP-1 Receptor Agonism as a Promising Approach for cSVD
-
Mar 9, 2026, 13:54Ahmed Ibrahim: Optimal Antithrombotic Therapy for Secondary Stroke Prevention in Patients with AF and ASCVD
-
Mar 9, 2026, 13:49Rick Matthews: Looking Beyond Clot Clearance in Long-Term Management After DVT
-
Mar 9, 2026, 13:43Genetic Technologies for Hemophilia Information Sheet Now Available in French and Spanish – WFH
-
Mar 9, 2026, 13:38Challenges in Hemophilia Care and Access to Treatment in Pakistan – Hemophilia Welfare Society Karachi Pakistan
-
Mar 9, 2026, 05:13Nicola Hancock: Shaping the Future of Stroke Care and the Stroke Action Plan for Europe at ELASF 2026
-
Mar 8, 2026, 16:19Simon Senanu: Crossmatch Procedures and Advanced Troubleshooting
-
Mar 8, 2026, 15:53Stuart Diamond: ApoB as a Key Marker of Cardiovascular Risk
-
Mar 8, 2026, 15:49Wolfgang Miesbach: Discussing Immunological Challenges in Hemophilia at GTH 2026